Clinical utility of the pan-immune-inflammation value in breast cancer patients

Qi, Xiaoyan; Qiao, Boyang; Song, Tingting; Huang, Dan; Zhang, Hui; Liu, Yang; Jin, Qi; Yang, Ming; Liu, Delong

doi:10.3389/fonc.2023.1223786

Cited by 10 publications

(4 citation statements)

References 50 publications

(60 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, a total of meta-analyses involving 2953 breast cancer patients investigated the prognostic significance of PIV (including OS, PFS, pCR [pathological complete response]), revealing cutoff values ranging from 205.1 to 438.7. 37 The optimal PIV cutoff value of 363.47, as determined in this study, falls within the range consistent with above findings. Based on the PWR reference value, Zhao et al discovered that patients with a PWR value of more than 25.38 had a poor prognosis.…”

Section: Discussionsupporting

confidence: 88%

“…Utilizing a restricted cubic spline (RCS) model, they determined an optimal critical value for PIV at 308.2. Furthermore, a total of meta‐analyses involving 2953 breast cancer patients investigated the prognostic significance of PIV (including OS, PFS, pCR [pathological complete response]), revealing cutoff values ranging from 205.1 to 438.7 37 . The optimal PIV cutoff value of 363.47, as determined in this study, falls within the range consistent with above findings.…”

Section: Discussionsupporting

confidence: 83%

See 1 more Smart Citation

Development and internal validation of a nomogram based on peripheral blood inflammatory markers for predicting prognosis in nasopharyngeal carcinoma

Lai,

Lin,

Zhuang

et al. 2024

Cancer Medicine

View full text Add to dashboard Cite

BackgroundInflammatory markers, including the product of neutrophil count, platelet count, and monocyte count divided by lymphocyte count (PIV) and the platelet‐to‐white blood cell ratio (PWR), have not been previously reported as prognostic factors in nasopharyngeal carcinoma (NPC) patients. In order to predict overall survival (OS) in NPC patients, our goal was to create and internally evaluate a nomogram based on inflammatory markers (PIV, PWR).MethodsA retrospective study was done on patients who received an NPC diagnosis between January 2015 and December 2018. After identifying independent prognostic indicators linked to OS using Cox proportional hazards regression analysis, we created a nomogram with the factors we had chosen.ResultsA total of 630 NPC patients in all were split into training (n = 441) and validation sets (n = 189) after being enrolled in a population‐based study in 2015–2018 and monitored for a median of 5.9 years. In the training set, the age, PIV, and PWR, selected as independent predictors for OS via multivariate Cox's regression model, were chosen to develop a nomogram. Both training and validation cohorts had C‐indices of 0.850 (95% confidence interval [CI]: 0.768–0.849) and 0.851 (95% CI: 0.765–0.877). Furthermore, compared with traditional TNM staging, our nomogram demonstrated greater accuracy in predicting patient outcomes. The risk stratification model derived from our prediction model may facilitate personalized treatment strategies for NPC patients.ConclusionOur findings confirmed the prognostic significance of the PWR and PIV in NPC. High PIV levels (>363.47) and low PWR (≤36.42) values are associated with worse OS in NPC patients.

show abstract

Section: Discussionsupporting

confidence: 88%

Section: Discussionsupporting

confidence: 83%

Development and internal validation of a nomogram based on peripheral blood inflammatory markers for predicting prognosis in nasopharyngeal carcinoma

Lai,

Lin,

Zhuang

et al. 2024

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…Furthermore, PIV's predictive efficiency was significantly superior to previously recognized inflammation-related markers [38]. A meta-analysis conducted by Qi et al, involving eight articles and 2953 patients with breast cancer, showed that elevated PIV in patients correlated with shorter OS and PFS [39]. In the context of bladder cancer specifically, Kayar et al discovered that an elevated PIV (>406.29) was associated with diminished OS and DFS [17].…”

Section: Discussionmentioning

confidence: 99%

Comparison of PIV and Other Immune Inflammation Markers of Oncological and Survival Outcomes in Patients Undergoing Radical Cystectomy

Russo,

Palermo,

Iacovelli

et al. 2024

Cancers

View full text Add to dashboard Cite

Inflammation is widely acknowledged as a significant characteristic of cancer, playing a substantial function in both the initiation and advancement of cancers. In this research, we planned to compare pan-immune inflammation markers and other well-known markers (systemic immune inflammation index and neutrophil to lymphocyte ratio) to predict prognosis in individuals treated with radical cystectomy for bladder cancer. Methods: In this retrospective analysis, we focused on preoperative PIV, systemic immune inflammation index (SII), and neutrophil–lymphocyte ratio (NLR) in 193 individuals managed with radical cystectomy for bladder cancer between January 2016 and November 2022. Multivariable logistic regression assessments were performed to assess the predictive capabilities of PIV, SII, and NLR for infiltration of lymph nodes (N), aggressive tumor stage (pT3/pT4), and any non-organ limited disease at the time of RC. Multivariable Cox regression analyses were conducted to assess the predictive impact of PIV on Relapse-free survival (RFS), Cancer-specific survival (CSS), and Overall survival (OS). Results: Our individuals were divided into high PIV and low PIV cohorts using the optimal cut-off value (340.96 × 109/L) based on receiver operating characteristic curve analysis for relapse-free survival. In multivariable preoperative logistic regression models, only SII and PIV correlated with the infiltration of lymph nodes, aggressive disease, and any non-organ confined disease. In multivariable Cox regression models considering presurgical clinicopathological variables, a higher PIV was associated with diminished RFS (p = 0.017) and OS (p = 0.029). In addition, in multivariable Cox regression models for postoperative outcomes, a high PIV correlated with both RFS (p = 0.034) and OS (p = 0.048). Conclusions: Our study suggests that PIV and SII are two very similar markers that may serve as independent and significant predictors of aggressive disease and worse survival impacts on individuals undergoing radical cystectomy for bladder neoplasm.

show abstract

“…In contrast to other inflammatory indexes, PIV combines all routinely assessed blood cell populations that reflect systemic inflammation and immunity. [ 109 ] As such, it provides a more complete picture of the host’s condition and is of more reliable value for prognostic assessment. However, there are few related studies on it, and more research is needed to explore it further.…”

Section: Peripheral Blood Inflammatory Indexes In Breast Cancermentioning

confidence: 99%

Peripheral blood inflammatory indexes in breast cancer: A review

Xie,

Guo,

Zhu

et al. 2023

Medicine

View full text Add to dashboard Cite

Immune and inflammatory responses play an important role in tumorigenesis and metastasis. Inflammation is an important component of the tumor microenvironment, and the changes in inflammatory cells may affect the occurrence and development of tumors. Complete blood count at the time of diagnosis and treatment can reflect the inflammatory status within the tumor. Studies have shown that the number of certain inflammatory cells in peripheral blood and their ratios are important prognostic factors for many malignancies, including neutrophil, lymphocyte, monocyte, and platelet counts, as well as neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, systemic immune-inflammation index, systemic inflammation response index and pan-immune-inflammation-value. The value of peripheral blood inflammation indexes in predicting the efficacy and prognosis of breast cancer neoadjuvant therapy is worth recognizing. This review details the application of peripheral blood inflammation indexes in the evaluation of efficacy and prediction of prognosis in neoadjuvant therapy for breast cancer, aiming to provide a more comprehensive reference for the comprehensive diagnosis and treatment of breast cancer.

show abstract

Clinical utility of the pan-immune-inflammation value in breast cancer patients

Cited by 10 publications

References 50 publications

Development and internal validation of a nomogram based on peripheral blood inflammatory markers for predicting prognosis in nasopharyngeal carcinoma

Development and internal validation of a nomogram based on peripheral blood inflammatory markers for predicting prognosis in nasopharyngeal carcinoma

Comparison of PIV and Other Immune Inflammation Markers of Oncological and Survival Outcomes in Patients Undergoing Radical Cystectomy

Peripheral blood inflammatory indexes in breast cancer: A review

Contact Info

Product

Resources

About